Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
Adverse effects should be monitored regularly with toxicity including gastrointestinal, hematologic, pulmonary, and hepatic. [123] Side effects such as nausea, vomiting or abdominal pain can be reduced by taking folic acid. [126] Rituximab combined with methotrexate appears to be more effective in improving symptoms compared to methotrexate ...
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
High dose: cerebral and cerebellar dysfunction, ocular toxicity, pulmonary toxicity, severe GI ulceration and peripheral neuropathy (rare). Decitabine: IV: DNA methyltransferase inhibitor. Myelodysplastic syndrome, sickle cell anaemia (orphan), acute myeloid leukaemia and chronic myeloid leukaemia.
In pharmacokinetics, a maintenance dose is the maintenance rate [mg/h] of drug administration equal to the rate of elimination at steady state. This is not to be confused with dose regimen , which is a type of drug therapy in which the dose [mg] of a drug is given at a regular dosing interval on a repetitive basis.
It is a promising treatment of renal diseases with proteinuria, in particular patients with resistance or partial response to rituximab. [10] A single low-dose infusion of Obinutuzumab, found to be effective and safe in inducing prolonged remission in children with steroid-dependent or frequently relapsing nephrotic syndrome.
A loading dose is most useful for drugs that are eliminated from the body relatively slowly, i.e. have a long systemic half-life. Such drugs need only a low maintenance dose in order to keep the amount of the drug in the body at the appropriate therapeutic level , but this also means that, without an initial higher dose, it would take a long ...